Chinese medical journal
-
Chinese medical journal · Oct 2022
Observational StudySwitching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study.
Recombinant human thrombopoietin (rh-TPO) and eltrombopag are two distinct TPO receptor agonists (TPO-RAs) with different mechanisms. During the pandemic, when immunosuppressive medications are controversial, switching to another TPO-RA may be worth exploring in patients who do not benefit from their first TPO-RA. We investigated the outcomes of switching from rh-TPO to eltrombopag or vice versa in immune thrombocytopenia (ITP) patients. ⋯ ClinicalTrials.gov, NCT04214951.
-
Chinese medical journal · Oct 2022
Transplant outcomes of 100 cases of living-donor ABO-incompatible kidney transplantation.
Although ABO-incompatible (ABOi) kidney transplantation (KT) has been performed successfully, a standard preconditioning regimen has not been established. Based on the initial antidonor ABO antibody titers, an individualized preconditioning regimen is developed, and this study explored the efficacy and safety of the regimen. ⋯ An individualized preconditioning regimen can achieve comparable graft and patient survival rates in ABOi KT with ABOc KT. Rit-free preconditioning effectively prevented AR without increasing the risk of infectious events in those with lower initial titers; however, antibody titer rebound should be monitored.